An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial

Clinical Cancer Research

Volumn 18, Issue 10, 2012, Pages 2976-2986

  De Fraipont, Florence ^a   Levallet, Guénaëlle ^d   Creveuil, Christian ^d   Bergot, Emmanuel ^d   Beau Faller, Michèle ^e   Mounawar, Mounia ^g   Richard, Nicolas ^d   Antoine, Martine ^h   Rouquette, Isabelle ^j   Favrot, Marie Christine ^a   Debieuvre, Didier ^k   Braun, Denis ^k   Westeel, Virginie ^l   Quoix, Elisabeth ^f   Brambilla, Elisabeth ^b   Hainaut, Pierre ^g   Moro Sibilot, Denis ^c   Morin, Franck ⁱ   Milleron, Bernard ^h,i   Zalcman, Gérard ^d  

^a Unité de Biochimie des Cancers et Biothérapies   (France)

^b INSTITUT ALBERT BONNIOT   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d CAEN UNIVERSITY HOSPITAL   (France)

^e HÔPITAL DE HAUTEPIERRE   (France)

^f UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^g INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^h HÔPITAL TENON   (France)

ⁱ ACTION Study Group   (France)

^j SERVICE DE PNEUMOLOGIE   (France)

^k Service de Pneumologie   (France)

^l UNIVERSITY HOSPITAL OF BESANÇON   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; PACLITAXEL; PROTEIN P53; TUMOR MARKER;

APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; DEATH ASSOCIATED PROTEIN KINASE 1 GENE; DISEASE FREE SURVIVAL; DISEASE MARKER; DNA METHYLATION; DOWN REGULATION; DRUG EFFICACY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOLECULAR MODEL; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; ONCOGENE K RAS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A GENE; RISK ASSESSMENT; TP53 GENE; TUMOR GENE; VALIDATION PROCESS;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CYTOSKELETON; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DNA METHYLATION; FEMALE; GENES, P53; GENES, RAS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; PROGNOSIS; PROMOTER REGIONS, GENETIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84861177200     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2797     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26: 3552-9.
3. Burdett S, Stewart LA, Rydzewska L. A systematic review and metaanalysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol 2006;1:611-21. (Pubitemid 47163946) (Pubitemid 47163946)
4. Berghmans T, Paesmans M, Meert AP, Mascaux C, Lothaire P, Lafitte JJ, et al. Survival improvement in resectable non-small cell lung cancer with neoadjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer 2005;49:13-23. (Pubitemid 40798089)
5. Zhu CQ, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol 2010;28:4417-24.
6. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, et al. A fivegene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007;356:11-20. (Pubitemid 46041749) (Pubitemid 46041749)
7. Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008;358:1118-28. (Pubitemid 351398486)
8. Westeel V, Milleron B, Quoix E, Breton JL, Braun D, PuyraveauM, et al. Results of the IFCT 0002 phase III study comparing a preoperative and a perioperative chemotherapy (CT) with two different CT regimens in resectable non-small cell lung cancer (NSCLC). J Clin Oncol 2009;27 Suppl; abstr 7530.
9. Inbal B, Cohen O,Polak-Charcon S, Kopolovic J, Vadai E, Eisenbach L, et al. DAP kinase links the control of apoptosis to metastasis. Nature 1997;390:180-4. (Pubitemid 27507988) (Pubitemid 27507988)
10. Oh HJ, Lee KK, Song SJ, Jin MS, Song MS, Lee JH, et al. Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. Cancer Res 2006;66:2562-9.
11. Raveh T, Droguett G, Horwitz MS, DePinho RA, Kimchi A. DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nat Cell Biol 2001;3:1-7. (Pubitemid 32114825) (Pubitemid 32114825)
12. Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 2001;20: 1509-18. (Pubitemid 32291201) (Pubitemid 32291201)
13. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001;93:691-9. (Pubitemid 32492810) (Pubitemid 32492810)
14. Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci 2007;120:3163-72. (Pubitemid 350018407) (Pubitemid 350018407)
15. Righini CA, de Fraipont F, Timsit JF, Faure C, Brambilla E, Reyt E, et al. Tumor-specific methylation in saliva: a promising biomarker for early detection of head and neck cancer recurrence. Clin Cancer Res 2007;13:1179-85. (Pubitemid 46424058) (Pubitemid 46424058)
16. Liu F, Killian JK, Yang M, Walker RL, Hong JA, Zhang M, et al. Epigenomic alterations and gene expression profiles in respiratory epithelia exposed to cigarette smoke condensate. Oncogene 2010;29:3650-64.
17. Zalcman G, Richard N, Hardouin A, Gervais R, Antoine M, Mittre H, et al. Routine detection of EGFR mutations in patients with NSCLC: a comparative study of three alternative methods in 105 patients. J Clin Oncol 2006;24 Suppl; abstr 7184.
18. Beau-Faller M, Legrain M, Voegeli AC, Guerin E, Lavaux T, Ruppert AM, et al. Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediatedPCRclamping. Br J Cancer 2009;100:985-92.
19. Le Calvez F, Mukeria A, Hunt JD, Kelm O, Hung RJ, Taniere P, et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res 2005;65:5076-83. (Pubitemid 40827316) (Pubitemid 40827316)
20. Beau-Faller M, Weber JC, Schneider A, Guerin E, Gasser B, Ducrocq X, et al. Genetic heterogeneity in lung and colorectal carcinoma as revealed by microsatellite analysis in plasma or tumor tissue DNA. Cancer 2003;97:2308-17. (Pubitemid 36444077) (Pubitemid 36444077)
21. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-8. (Pubitemid 32494397) (Pubitemid 32494397)
22. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990;9:811-8. (Pubitemid 20343989) (Pubitemid 20343989)
23. Sauerbrei W, Royston P. Building multivariable prognostic and diagnostic models: transformation of the predictors by using fractional polynomials. J Roy Stat Soc Series A 1999;162: 71-94.
24. Harrell FJ, Lee K, Mark D. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87. (Pubitemid 26072233) (Pubitemid 26072233)
25. Lindsay C, Scholz A, Morozov V, Ishov A. Daxx shortens mitotic arrest caused by paclitaxel. Cell Cycle 2007;6:1200-04. (Pubitemid 47327986) (Pubitemid 47327986)
26. Boettcher M, Kischkel F,Hoheisel JD. High-definitionDNAmethylation profiles from breast and ovarian carcinoma cell lines with differing doxorubicin resistance. PLoS One 2010;5:e11002.
27. Chang JW, Hsu HS, Ni HJ, Chuang CT, Hsiung CH, Huang TH, et al. Distinct epigenetic domains separated by a CTCF bound insulator between the tandem genes, BLU and RASSF1A. PLoS One 2010;5: e12847.
28. Schagdarsurengin U, Gimm O, Hoang-Vu C, Dralle H, Pfeifer GP, Dammann R. Frequent epigenetic silencing of theCpGisland promoter of RASSF1A in thyroid carcinoma. Cancer Res 2002;62:3698-701. (Pubitemid 34728849) (Pubitemid 34728849)
29. Yan PS, Shi H, Rahmatpanah F, Hsiau TH, Hsiau AH, Leu YW, et al. Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer. Cancer Res 2003;63:6178-86. (Pubitemid 37255161) (Pubitemid 37255161)
30. Buckingham L, Penfield Faber L, Kim A, Liptay M, Barger C, Basu S, et al. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer 2010;126:1630-9.
31. Kim DH, Kim JS, Ji YI, Shim YM, Kim H, Han J, et al. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Res 2003;63:3743-6. (Pubitemid 36793061) (Pubitemid 36793061)
32. Yanagawa N, Tamura G, Oizumi H, Kanauchi N, Endoh M, Sadahiro M, et al. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected nonsmall cell lung cancers. Lung Cancer 2007;58:131-8. (Pubitemid 47379969) (Pubitemid 47379969)
33. Kim DH, Kim JS, Park JH, Lee SK, Ji YI, Kwon YM, et al. Relationship of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer. Cancer Res 2003;63:6206-11. (Pubitemid 37255165) (Pubitemid 37255165)
34. Kim YT, Park SJ, Lee SH, Kang HJ, Hahn S, Kang CH, et al. Prognostic implication of aberrant promoter hypermethylation of CpG islands in adenocarcinoma of the lung. J Thorac Cardiovasc Surg 2005;130: 1378.
35. Filipits M, Pirker R, Dunant A, Lantuejoul S, Schmid K, Huynh A, et al. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J Clin Oncol 2007;25:2735-40. (Pubitemid 47123181) (Pubitemid 47123181)
36. Kraunz KS, Nelson HH, Lemos M, Godleski JJ, Wiencke JK, Kelsey KT. Homozygous deletion of p16INK4a and tobacco carcinogen exposure in nonsmall cell lung cancer. Int J Cancer 2006;118:1364-9.
37. Zalcman G, Beau-Faller M, Creveuil C, de Fraipont F, Mounawar M, Richard N, et al. Use of Ras effector RASSF1A promoter gene methylation and chromosome 9p loss of heterozygosity (LOH) to predict progression-free survival (PFS) in perioperative chemotherapy (CT) phase III trial IFCT-0002 in resectable non-small cell lung cancer. J Clin Oncol 2008;26 Suppl; abstr 7500.
38. Tomizawa Y, Kohno T, Kondo H, Otsuka A, Nishioka M, Niki T, et al. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clin Cancer Res 2002;8:2362-8. (Pubitemid 34753611) (Pubitemid 34753611)
39. Wang J, Lee JJ, Wang L, Liu DD, Lu C, Fan YH, et al. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin Cancer Res 2004;10:6119-25. (Pubitemid 39287517) (Pubitemid 39287517)
40. Riaz N. DNA methylation in lung cancer. N Engl J Med 2008;358:2514; Author reply.
41. Vos MD, Martinez A, Elam C, Dallol A, Taylor BJ, Latif F, et al. A role for the RASSF1A tumor suppressor in the regulation of tubulin polymerization and genomic stability. Cancer Res 2004;64:4244-50.
42. van der Weyden L, Tachibana KK, Gonzalez MA, Adams DJ, Ng BL, Petty R, et al. The RASSF1A isoform of RASSF1 promotes microtubule stability and suppresses tumorigenesis. Mol Cell Biol 2005;25: 8356-67.
43. Kim YT, Lee SH, Sung SW, Kim JH. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection? Ann Thorac Surg 2005;79:1180-8; discussion 1180-8.
44. Safar AM, SpencerH3rd, Su X, Coffey M, Cooney CA, Ratnasinghe LD, et al. Methylation profiling of archived non-small cell lung cancer: a promising prognostic system. Clin Cancer Res 2005;11:4400-5.
45. Tang X, Khuri FR, Lee JJ, Kemp BL, Liu D, Hong WK, et al. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst 2000;92:1511-6.
46. Harden SV, Tokumaru Y, Westra WH, Goodman S, Ahrendt SA, Yang SC, et al. Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res 2003;9:1370-5. (Pubitemid 36418388) (Pubitemid 36418388)
47. Lu C, Soria JC, Tang X, Xu XC, Wang L, Mao L, et al. Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol 2004;22:4575-83. (Pubitemid 41185125) (Pubitemid 41185125)
48. Reddy AN, JiangWW,Kim M, Benoit N, Taylor R, Clinger J, et al. Deathassociated protein kinase promoter hypermethylation in normal human lymphocytes. Cancer Res 2003;63:7694-8. (Pubitemid 37466698) (Pubitemid 37466698)
49. Raval A, Tanner SM, Byrd JC, Angerman EB, Perko JD, Chen SS, et al. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 2007;129:879-90. (Pubitemid 46813150) (Pubitemid 46813150)
50. Vaissiere T, Hung RJ, Zaridze D, Vineis P, Hoek G, Krzyzanowski M, et al. Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors. Cancer Res 2009;69:243-52.